Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19+ Lymphoma, B-Cell”

594 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 594 results

Testing effectiveness (Phase 2)Looking for participantsNCT07097207
What this trial is testing

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital 20
Early research (Phase 1)Ended earlyNCT03103971
What this trial is testing

HuJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+14 more
Fred Hutchinson Cancer Center 55
Early research (Phase 1)Study completedNCT05149391
What this trial is testing

C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Who this might be right for
B Cell Non-Hodgkin's Lymphoma
Peking University 3
Early research (Phase 1)Active Not RecruitingNCT04049513
What this trial is testing

ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

Who this might be right for
Lymphomas Non-Hodgkin's B-CellDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)+3 more
Malaghan Institute of Medical Research 30
Testing effectiveness (Phase 2)Looking for participantsNCT06045910
What this trial is testing

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell+3 more
Cancer Research UK 84
Early research (Phase 1)Active Not RecruitingNCT01430390
What this trial is testing

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Who this might be right for
Acute Lymphocytic LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 19
Early research (Phase 1)Looking for participantsNCT06830031
What this trial is testing

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell-lymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3B+3 more
Shanghai Exuma Biotechnology Ltd. 18
Testing effectiveness (Phase 2)UnknownNCT05385263
What this trial is testing

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Who this might be right for
B Cell Lymphoma
Tel-Aviv Sourasky Medical Center 20
Early research (Phase 1)Active Not RecruitingNCT02935257
What this trial is testing

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19

Who this might be right for
Leukemia, Lymphoblastic, Acute, Lymphoma
University College, London 72
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Testing effectiveness (Phase 2)Looking for participantsNCT05643742
What this trial is testing

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
B-cell LymphomaNon-Hodgkin LymphomaB-cell Malignancy+5 more
CRISPR Therapeutics AG 120
Early research (Phase 1)Ended earlyNCT02702141
What this trial is testing

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaDLBCLDiffuse Large B-cell Lymphoma+1 more
Seagen Inc. 44
Testing effectiveness (Phase 2)Looking for participantsNCT05674175
What this trial is testing

Co-administration of CART22-65s and huCART19 for B-ALL

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD 93
Early research (Phase 1)UnknownNCT05210907
What this trial is testing

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Seoul National University Hospital 5
Early research (Phase 1)UnknownNCT03298828
What this trial is testing

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Who this might be right for
Acute Lymphoblastic LeukemiaBurkitt Lymphoma
Third Military Medical University 30
Testing effectiveness (Phase 2)Temporarily pausedNCT07098364
What this trial is testing

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
Fred Hutchinson Cancer Center 33
Early research (Phase 1)Ended earlyNCT05318963
What this trial is testing

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Who this might be right for
B-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Institute of Hematology & Blood Diseases Hospital, China 14
Early research (Phase 1)Study completedNCT03029338
What this trial is testing

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Who this might be right for
Lymphomas Non-Hodgkin's B-CellRelapse
Institute of Hematology & Blood Diseases Hospital, China 20
Early research (Phase 1)WithdrawnNCT07049432
What this trial is testing

N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Who this might be right for
B-cell Non Hodgkin Lymphoma
University of Utah
Early research (Phase 1)Ended earlyNCT03379493
What this trial is testing

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Who this might be right for
Lymphomas Non-Hodgkin's B-Cell
Eureka Therapeutics Inc. 4
Next Page